Abstract:OBJECTIVE:To identify potential prognosis related clinical and molecular factors in malignant pleural mesothelioma (MPM).METHODS:Seventy-nine patients with MPM treated in Beijing Cancer Hospital from June 1996 to May 2012 were enrolled in this study. Clinical and pathological data were collected, including age, gender, smoking status, treatment, response, and molecular biomarkers such as thymidylate synthetase (TS) expression, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangement. The primary endpoint was overall survival (OS). SPSS 16.0 statistical analysis software was used for univariate analysis. The expression of TS was detected by immunohistochemistry (IHC). Fluorescence in situ hybridization (FISH) was performed to detect EML4-ALK gene rearrangement. Efficacy of the chemotherapy regimen including pemetrexed was analyzed with these molecular biomarkers.RESULTS:The median survival time (MST) of all patients was 15.5 months (95% CI: 10.6 - 20.4). Univariate survival analysis revealed that treatment factors including receiving operation, systemic chemotherapy, pemetrexed-based chemotherapy and capability of receiving second (or above) line chemotherapy were significantly related with OS. The MST of patients receiving operation was 5.4 months (95% CI: 3.6 - 7.3), significantly shorter than the 17.7months (95% CI: 11.8 - 23.5) in those who didn't receive operation (P = 0.030). Patients receiving systemic chemotherapy had a longer MST of 18.0 months (95% CI: 12.3 - 23.8) as compared to the 7.9 months (95% CI: 1.1 - 14.7) in those who didn't (P = 0.001). The MST of pemetrexed-based chemotherapy was 21.9 months (95% CI: 14.1-29.7) compared with 8.8 months (95% CI: 4.2 - 13.4) of regimens without pemetrexed (P = 0.000). For patients capable of receiving second (or above) line chemotherapy the MST was longer (21.0 months, 95% CI: 12.7 - 29.3) than those who could not (12.1 month, 95% CI: 6.4 - 17.8 month), P = 0.022. For the 42 patients treated with pemetrexed-based chemotherapy, the objective response rate (ORR) was 33.3% (14/42), the disease control rate (DCR) was 78.6% (33/42), the median progression-free survival (PFS) was 4.8 months (95% CI: 3.6 - 6.0) and MST was 21.9 months (95% CI: 14.1 - 29.7). Twenty-nine patients provided adequate specimens for detection of TS expression and 6 cases (20.7%) were positive. EML4-ALK gene rearrangement was studied in 32 patients and 6 (18.8%) were positive. TS expression was found to be inversely related to PFS of pemetrexed-based chemotherapy (P = 0.041). The MST was 19.6 months (95% CI: 6.0 - 7.9) in EML4-ALK-positive patients and 9.57 months (95% CI: 2.7 - 4.3) in negative ones (P = 0.159).CONCLUSIONS:Systemic chemotherapy especially pemetrexed-based regimen was proved to be a superior option for MPM with a significantly prolonged OS. Correlation between TS expression or EML4-ALK rearrangement and outcome of pemetrexed-based chemotherapy for MPM may contribute to future individualized treatment, which needs further validation from large-scale prospective studies.

Prognostic Significance of Soluble Mesothelin in Malignant Pleural Mesothelioma: a Meta-Analysis

Role of Prosaposin and Extracellular Sulfatase Sulf-1 Detection in Pleural Effusions as Diagnostic Biomarkers of Malignant Mesothelioma

Application of LMLC Prognostic Score in Survival Predicting of Malignant Pleural Effusion Secondary to Pleural Mesothelioma

Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma

Mesothelin Expression is Associated with Poor Outcomes in Breast Cancer

Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Patients with Malignant Pleural Mesothelioma: a Meta-Analysis.

Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome

Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial

Prognostic significance of inflammation-related and electrolyte laboratory variables in patients with malignant pleural mesothelioma

PD-L1 Expression Associated with Worse Survival Outcome in Malignant Pleural Mesothelioma.

Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma

[Prognosis Related Clinical and Molecular Factors in Malignant Pleural Mesothelioma].

Prognostic Significance of Solitary Lymph Node Metastasis in Patients with Squamous Cell Carcinoma of Middle Thoracic Esophagus

Prognostic Significance of Circulating Soluble Programmed Death Ligand-1 in Patients with Solid Tumors

Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis

Diagnostic and Prognostic Values of Endothelial-Cell-Specific Molecule-1 with Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer

[Survival Analysis of 37 Cases of Malignant Mesothelioma].

Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma

Prognostic Significance of Serum Smica Levels in Non-Small Cell Lung Cancer.

Association Between Mesothelin Expression and Survival Outcomes in Patients with Triple-Negative Breast Cancer: a Protocol for a Systematic Review

Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis